for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GT Biopharma Inc

GTBP.OQ

Latest Trade

15.10USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.91

 - 

17.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.10
Open
--
Volume
--
3M AVG Volume
14.24
Today's High
--
Today's Low
--
52 Week High
17.40
52 Week Low
3.91
Shares Out (MIL)
28.39
Market Cap (MIL)
451.18
Forward P/E
-16.21
Dividend (Yield %)
--

Latest Developments

More

Gt Biopharma Says Have Applied To List Our Common Stock On Nasdaq Capital Market Under Symbol “GTBP.”

Gt Biopharma Intends To Apply To List Common Stock On The Nasdaq Capital Market Under The Symbol “GTBP”

GT Biopharma Announces Sale Of Its Fixed Dose Combination Tablet (Gtb-004) For Myasthenia Gravis (Chronic Autoimmune Disease) To Das Therapeutics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GT Biopharma Inc

GT Biopharma, Inc., formerly OXIS International, Inc., is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates, bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic agents. Its drug candidates include OXS-1550, OXS-2175 and OXS-4235. OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate. OXS-2175 is a small molecule therapeutic candidate for the treatment of triple-negative breast cancer. OXS-4235 is also a small molecule therapeutic candidate. It is engaged in developing central nervous system (CNS) drugs.

Industry

Biotechnology & Drugs

Contact Info

9350 WILSHIRE BLVD., SUITE 203

BEVERLY HILLS, CA

90212

United States

+1.310.5514020

https://www.gtbiopharma.com/

Executive Leadership

Anthony J. Cataldo

Chairman of the Board, President, Chief Executive Officer

Steven W. Weldon

Chief Financial Officer, Director

Michael D. Handelman

Chief Financial Officer

Geoffrey S. Miller

Consulting Chief Scientific Officer

Gregory I. Berk

Chief Medical Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-6.415

2021(E)

-0.980
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-934.32

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up